Each record shows the current regulatory status for a peptide, including controlling sources, as-of dates, and what the status does and does not mean.
FDA-approved drug product: Not an approved drug
Also known as: Body Protection Compound-157, Bepecin, PL-14736
A synthetic 15-amino-acid peptide. It has no USAN, no USP/NF monograph, and is not a component of an FDA-approved drug. Commercial products may be sold as BPC-157 acetate or BPC-157 free base, which are distinct active pharmaceutical ingredients.
FDA-approved drug product: Not an approved drug
Also known as: Copper peptide GHK-Cu, glycyl-L-histidyl-L-lysine copper
A tripeptide-copper complex. It is not a component of an FDA-approved drug. FDA's categorization differs by route of administration.
FDA-approved drug product: Not an approved drug
Also known as: Ipamorelin acetate, NNC 26-0091
A synthetic pentapeptide growth hormone secretagogue. No USAN or USP/NF monograph; not a component of an FDA-approved drug.
FDA-approved drug product: Not an approved drug
Also known as: MT-II, Melanotan 2
A synthetic melanocortin peptide. It is not a component of an FDA-approved drug and has no USP/NF monograph.
FDA-approved drug product: Approved product — specific indication/route
Also known as: PT-141, Vyleesi
A melanocortin receptor agonist peptide. FDA approved it as Vyleesi for a specific premenopausal HSDD indication.
FDA-approved drug product: Not an approved drug / investigational
Also known as: LY3437943, RETA
A triple agonist of GIP, GLP-1, and glucagon receptors. It is an investigational drug and is not a component of any FDA-approved product.
FDA-approved drug product: Approved product — specific indication/route
Also known as: Ozempic, Rybelsus, Wegovy
A GLP-1 receptor agonist approved in three FDA-approved products with different routes, indications, and strengths.
FDA-approved drug product: Approved product discontinued from marketing
Also known as: Sermorelin acetate, Geref
A growth hormone-releasing hormone analog. Geref (sermorelin acetate) was FDA approved but is discontinued from marketing per Drugs@FDA. It remains a component of a previously approved drug.
FDA-approved drug product: Approved product — specific indication/route
Also known as: Egrifta, TH9507
A growth hormone-releasing factor analog. FDA has approved it in Egrifta for a specific HIV-associated indication.
FDA-approved drug product: Approved product — specific indication/route
Also known as: LY3298176, Mounjaro, Zepbound
A dual GIP/GLP-1 receptor agonist peptide. FDA has approved it as the active ingredient in Mounjaro and Zepbound for specific indications, routes, strengths, and products.